Caricamento...
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and the US for use in patients with type 2 diabetes...
Salvato in:
| Pubblicato in: | Ther Adv Endocrinol Metab |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406879/ https://ncbi.nlm.nih.gov/pubmed/25941564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018814560735 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|